AP
RMD icon

Arlington Partners’s ResMed RMD Stock Holding History

Arlington Partners’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-424
Closed -$92.6K – 548
2023
Q2 		$92.6K Hold
424
– – 0.01% 256
2023
Q1 		$92.9K Sell
424
-185
-30% -$40.1K 0.01% 210
2022
Q4 		$127K Hold
609
– – 0.02% 124
2022
Q3 		$133K Hold
609
– – 0.05% 109
2022
Q2 		$128K Hold
609
– – 0.04% 137
2022
Q1 		$148K Hold
609
– – 0.04% 138
2021
Q4 		$159K Buy
+609
New +$158K 0.04% 144

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Arlington Partners's RMD Position: Q3 2023 in Review

Arlington Partners sold out of ResMed (RMD) in Q3 2023, closing a stake of 424 shares — an estimated $92.6K sold.

Arlington Partners first reported a position in RMD in Q4 2021 and held it in 7 quarters. The position peaked at $159K in Q4 2021. 657 funds tracked by Wall St. Rank hold RMD as of Q3 2023.

  • Arlington Partners reported no remaining ResMed position as of Q3 2023 after selling out during the quarter.
  • Arlington Partners sold 424 ResMed shares in Q3 2023, an estimated $92.6K.
  • Arlington Partners first reported a position in ResMed in Q4 2021 and held it in 7 quarters.
  • Arlington Partners's ResMed position peaked at $159K in Q4 2021.
  • 657 funds tracked by Wall St. Rank held ResMed as of Q3 2023.

Based on Arlington Partners's 13F filing for Q3 2023, filed 24 Oct 2023.